Discontinuation of the Development of a Regenerative Medicine Product (CL2020) Using Muse Cells
February 14, 2023
The Mitsubishi Chemical Group ("the Group") has decided to discontinue the development of a regenerative medicine product (CL2020) using Muse Cells*.
The Group has been actively developing and investing in the research and development of regenerative medicine products using Muse Cells since 2015. However, after comprehensive and careful consideration of the latest clinical developments, timelines for commercialization, and its pharmaceutical business strategy going forward, the Group has decided to discontinue the development of CL2020.
* Muse Cells: Multilineage-differentiating Stress-Enduring Cells
The Group has been actively developing and investing in the research and development of regenerative medicine products using Muse Cells since 2015. However, after comprehensive and careful consideration of the latest clinical developments, timelines for commercialization, and its pharmaceutical business strategy going forward, the Group has decided to discontinue the development of CL2020.
* Muse Cells: Multilineage-differentiating Stress-Enduring Cells
